The interplay between a CF patient's microbial communities and their health is complex. The first talk in this session will illustrate how the gut microbiome influences the rate of clinical exacerbations through changes in immune signaling. The next talk will describe how Pseudomonas aeruginosa undergoes adaptive evolution in the sinuses of CF patients, potentially seeding the lungs with pathoadapted strains. The last three talks will explore the microbial community structure and function in the CF lung -- first by coupling genomics and metabolomics to identify biomarkers of disease progression, then by exploring how targeting a specific metabolism of P. aeruginosa, nitrate respiration, can kill antibiotic-tolerant bacteria, and finally by demonstrating how the commonly used antibiotic tobramycin primarily targets non-dominant taxa in the CF lung.
Demonstrate that the activity of bacterial communities at multiple sites in the human body affect the health of CF patients.
Illustrate the utility of understanding the metabolic state of CF pathogens in order to identify biomarkers of disease progression and to develop novel treatments.
Assess the ecological impact of treatment with tobramycin.